Cancer vaccine (BN ImmunoTherapeutics/National Cancer Institute)

A phase I trial of AIC100, a novel CAR T-cell therapy targeting ICAM-1, demonstrated a 50% response rate in anaplastic thyroid cancer patients at higher dose levels, with one complete and one partial response.

A groundbreaking study reveals that blocking ICAM1 improves blood flow recovery in ischemic muscles of diabetic mice, offering new insights into treating chronic limb-threatening ischemia (CLTI). The research highlights the role of endothelial adhesiveness and the potential of ICAM1 blocking antibodies as a therapeutic target for CLTI, especially in diabetic conditions.

Alicaforsen, an ICAM-1 inhibitor, has demonstrated effectiveness in treating ulcerative colitis and shows potential for pouchitis, with ongoing phase 3 trials. Its safety profile in UC patients is favorable, and it has received orphan designation for pouchitis treatment.